Literature DB >> 27016233

Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.

Dmitriy Zamarin1, Amir A Jazaeri2.   

Abstract

During the past decade significant progress in the understanding of stimulatory and inhibitory signaling pathways in immune cells has reinvigorated the field of immuno-oncology. In this review we outline the current immunotherapy based approaches for the treatment of gynecological cancers, and focus on the emerging clinical data on immune checkpoint inhibitors, adoptive cell therapies, and vaccines. It is anticipated that in the coming years biomarker-guided clinical trials, will provide for a better understanding of the mechanisms of response and resistance to immunotherapy, and guide combination treatment strategies that will extend the benefit from immunotherapy to patients with gynecologic cancers.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Checkpoint inhibitors; Endometrial cancer; Gynecologic cancers; Immuno-oncology; Immunotherapy; Ovarian cancer

Mesh:

Substances:

Year:  2016        PMID: 27016233      PMCID: PMC5007873          DOI: 10.1016/j.ygyno.2015.12.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  163 in total

1.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Authors:  L Muderspach; S Wilczynski; L Roman; L Bade; J Felix; L A Small; W M Kast; G Fascio; V Marty; J Weber
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

2.  Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.

Authors:  Gerald Willimsky; Thomas Blankenstein
Journal:  Nature       Date:  2005-09-01       Impact factor: 49.962

3.  IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Authors:  Mythili Koneru; Terence J Purdon; David Spriggs; Susmith Koneru; Renier J Brentjens
Journal:  Oncoimmunology       Date:  2015-01-23       Impact factor: 8.110

Review 4.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

7.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

Authors:  G E Peoples; P S Goedegebuure; R Smith; D C Linehan; I Yoshino; T J Eberlein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.

Authors:  Mythili Koneru; Roisin O'Cearbhaill; Swati Pendharkar; David R Spriggs; Renier J Brentjens
Journal:  J Transl Med       Date:  2015-03-28       Impact factor: 5.531

View more
  13 in total

1.  Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.

Authors:  Ying L Liu; Qin Zhou; Alexia Iasonos; Vivian N Emengo; Claire Friedman; Jason A Konner; Roisin E O'Cearbhaill; Carol Aghajanian; Dmitriy Zamarin
Journal:  Gynecol Oncol       Date:  2019-08-14       Impact factor: 5.482

2.  Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.

Authors:  Dmitriy Zamarin; Robert A Burger; Michael W Sill; Daniel J Powell; Heather A Lankes; Michael D Feldman; Oliver Zivanovic; Camille Gunderson; Emily Ko; Cara Mathews; Sudarshan Sharma; Andrea R Hagemann; Samir Khleif; Carol Aghajanian
Journal:  J Clin Oncol       Date:  2020-04-10       Impact factor: 44.544

3.  Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).

Authors:  Anne M Mills; Lauren C Peres; Alice Meiss; Kari L Ring; Susan C Modesitt; Sarah E Abbott; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Kristin Wallace; Joellen M Schildkraut
Journal:  Int J Gynecol Pathol       Date:  2019-03       Impact factor: 2.762

4.  Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites.

Authors:  Ana Laura Alfano; Alejandro Nicola Candia; Nicasio Cuneo; Leandro N Guttlein; Alejandro Soderini; Cecilia Rotondaro; Leonardo Sganga; Osvaldo L Podhajcer; M Veronica Lopez
Journal:  Mol Ther Oncolytics       Date:  2017-06-16       Impact factor: 7.200

5.  A Leishmania murine model to evaluate the immunomodulatory properties of Pythium insidiosum proteins.

Authors:  Tatiana Maria Inêz-Ferreira; Leonel Mendoza; Raquel Vilela; Hélida Monteiro de Andrade; João Paulo Haddad; Fernanda Freire Campos Nunes; Isabela Moreira Gondim; Tânia Mara Pinto Dabés Guimarães; Vicente de Paulo Coelho Peixoto de Toledo
Journal:  Heliyon       Date:  2017-03-30

Review 6.  Update on immune checkpoint inhibitors in gynecological cancers.

Authors:  Valerie Heong; Natalie Ngoi; David Shao Peng Tan
Journal:  J Gynecol Oncol       Date:  2016-12-14       Impact factor: 4.401

7.  The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.

Authors:  Muna Alemi Yahya; Shilhav Meisel Sharon; Shay Hantisteanu; Mordechai Hallak; Ilan Bruchim
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-05       Impact factor: 5.555

Review 8.  Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.

Authors:  Ying L Liu; Dmitriy Zamarin
Journal:  Curr Oncol Rep       Date:  2018-11-13       Impact factor: 5.075

Review 9.  Vaginal Microbiota and HPV Infection: Novel Mechanistic Insights and Therapeutic Strategies.

Authors:  Yuanyue Li; Tao Yu; Huang Yan; Duanduan Li; Tang Yu; Tao Yuan; Abdul Rahaman; Shahid Ali; Farhat Abbas; Ziqin Dian; Xiaomei Wu; Zulqarnain Baloch
Journal:  Infect Drug Resist       Date:  2020-04-30       Impact factor: 4.003

Review 10.  Epigenetic therapy for ovarian cancer: promise and progress.

Authors:  Sara Moufarrij; Monica Dandapani; Elisa Arthofer; Stephanie Gomez; Aneil Srivastava; Micael Lopez-Acevedo; Alejandro Villagra; Katherine B Chiappinelli
Journal:  Clin Epigenetics       Date:  2019-01-15       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.